Lung involvement at presentation predicts disease activity and permanent organ damage at 6, 12 and 24 months follow - up in ANCA - associated vasculitis

BMC Immunology

Volumn 15, Issue 1, 2014, Pages

  Hassan, Tidi M ^a   Hassan, Astrid S ^a   Igoe, Ann ^a   Logan, Mark ^a   Gunaratnam, Cedric ^a   McElvaney, Noel G ^a   O'Neill, Shane J ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

ANCA; Pulmonary hemorrhage; Vasculitis

Indexed keywords

CREATININE; NEUTROPHIL CYTOPLASMIC ANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; ANCA ASSOCIATED VASCULITIS; ARTICLE; BIRMINGHAM VASCULITIS ACTIVITY SCORE 3; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GRANULOMATOSIS WITH POLYANGIITIS; HUMAN; KIDNEY DISEASE; LUNG DISEASE; LUNG FIBROSIS; LUNG GRANULOMATOSIS; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC POLYANGIITIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; ORGAN INJURY; OUTCOME ASSESSMENT; PROGNOSIS; VASCULITIS DAMAGE INDEX; AIRWAY OBSTRUCTION; ASTHMA; BIRMINGHAM VASCULITIS ACTIVITY SCORE; BRONCHIECTASIS; CLINICAL ASSESSMENT TOOL; CORONARY ARTERY DISEASE; HEART ARREST; HEART INFARCTION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LUNG INFARCTION; LUNG INVOLVEMENT; LUNG NODULE; MORBIDITY; NOSE DISEASE; OVERALL SURVIVAL; PHENOTYPE; PLEURAL FIBROSIS; POLYARTERITIS NODOSA; PREDICTION; PULMONARY HYPERTENSION; RELAPSE; RESPIRATORY FAILURE; SUBGLOTTIC STENOSIS; SURVIVAL RATE; THORAX RADIOGRAPHY; WEGENER GRANULOMATOSIS;

ADULT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG; MALE; MIDDLE AGED; PHENOTYPE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; VASCULITIS;

EID: 84904753506     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-15-20     Document Type: Article

References (27)

1. Little MA, Nightingale P, Verburgh CA, Hauser T, De Groot K, Savage C, Jayne D, Harper L, . European Vasculitis Study (EUVAS) Group Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010, 69:1036-1043. 10.1136/ard.2009.109389, 19574233, European Vasculitis Study (EUVAS) Group.
2. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 1958, 2:265-270. 10.1136/bmj.2.5091.265, 2026251, 13560836.
3. Gordon M, Luqmani RA, Adu D, Greaves I, Richards N, Michael J, Emery P, Howie AJ, Bacon PA. Relapses in patients with a systemic vasculitis. Q J Med 1993, 86:779-789.
4. Mahr A, Katsahian S, Varet H, Guillevin L, Hagen EC, Höglund P, Merkel PA, Pagnous C, Rasmussen N, Westman K, Jayne D, . French Vasculitis Study Group (FVSG) and the European Vasculitis Society (EUVAS) Revisiting the classification of clinical phenotypes of antineutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Ann Rheum Dis 2013, 72:1003-1010. 10.1136/annrheumdis-2012-201750, 22962314, French Vasculitis Study Group (FVSG) and the European Vasculitis Society (EUVAS).
5. Kamali S, Erer B, Artim-Esen B, Gul A, Ocal L, Konice M, Aral O, Inanc M. Predictors of damage and survival in patients with Wegener's granulomatosis: analysis of 50 patients. J Rheumatol 2010, 37:374-378. 10.3899/jrheum.090387, 20008921.
6. Frankel SK, Schwarz MI. The pulmonary vasculitides. Am J Respir Crit Care Med 2012, 186:216-224. 10.1164/rccm.201203-0539CI, 22679011.
7. Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with anti-neutrophil cytoplasmic autoantibody associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol 1996, 7:23-32.
8. Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nölle B, Heller M, Gross WL. An interdisplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000, 43:1021-1032. 10.1002/1529-0131(200005)43:5<1021::AID-ANR10>3.0.CO;2-J, 10817555.
9. Zycinska K, Wardyn KA, Tyszko P, Otto M. Analysis of early death based on the prediction model in Wegener's granulomatosis with pulmonary and renal involvement. J Physiol Pharmacol 2007, 58(Suppl 5):829-837.
10. Kostianovsky A, Hauser T, Pagnoux C, Cohen P, Daugas E, Mouthon L, Miossec P, Cordier JP, Gueillevin L, . French Vasculitis Study Group (FVSG) Alveolar haemorrhage in ANCA associated vasculitides: 80 patients' features and prognostic factors. Clin Exp Rheumatol 2012, 30(70):S77-S82. French Vasculitis Study Group (FVSG).
11. Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Le Toumelin P. The Five Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group cohort. Medicine (Baltimore) 2011, 90:19-27. 10.1097/MD.0b013e318205a4c6, 21200183.
12. Exley AR, Bacon PA. Clinical disease activity in systemic vasculitis. Curr Opin Rheumatol 1996, 8:12-18. 10.1097/00002281-199601000-00002, 8867533.
13. Luqmani RA, Flossmann O. Outcome in small-vessel systemic vasculitis. J Rheumatol 2006, 33:1224-1227.
14. Pavone L, Grasselli C, Chierici E, Maggiore U, Garini G, Ronda N, Manganelli P, Pesci A, Rioda WT, Tumiati B, Pavesi G, VAglio A, Buzio C, . Secondary and Primer Vasculitides Study Group Outcome and prognostic factors during the course of primary small-vessel vasculitdes. J Rheumatol 2006, 33:1299-1306. Secondary and Primer Vasculitides Study Group.
15. Bhamra K, Luqmani R. Damage assessment in ANCA-associated vasculitis. Curr Rheumatol Rep 2012, 14:494-500. 10.1007/s11926-012-0291-1, 22983618.
16. Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, Falk RJ, Guillevin L, Nachman PH. Predictors of relapse and treatment resistant in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med 2005, 143:621-631. 10.7326/0003-4819-143-9-200511010-00005, 16263884.
17. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole for the prevention of relapses of Wegener's granulomatosis. French Vasculitis Study Group. N Engl J Med 1996, 335:16-20. 10.1056/NEJM199607043350103, 8637536.
18. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983, 98:76-85. 10.7326/0003-4819-98-1-76, 6336643.
19. Anderson G, Coles ET, Crane M, Douglas AC, Gibbs AR, Geddes DM, Peel ET, Wood JB. Wegener's granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee. Q J Med 1992, 83:427-438.
20. Mukhtyar C, Lee R, Brown D, Carruthers D, Dasgupta B, Dubey S, Flossmann O, Hall C, Hollywood J, Jayne D, Jones R, Lanyon P, Muir A, Scott D, Young L, Luqmani RA. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009, 68:1827-1832. 10.1136/ard.2008.101279, 19054820.
21. Gayraud M, Guillevin L, le Toumelin P, Cohen P, Lhote F, Casassus P, Jarrousse B, . French Vasculitis Study Group Long-term follow-up of polyarteritis nodosa, microsocopic polyangiitis and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001, 44:666-675. 10.1002/1529-0131(200103)44:3<666::AID-ANR116>3.0.CO;2-A, 11263782, French Vasculitis Study Group.
22. Koldingsnes W, Nossent JC. Basline features and intial treatment as predictors of remission and relapse in Wegener's granulomatosis. J Rheumatol 2003, 30:80-88.
23. Exley AR, Bacon PA, Luqmani RA, Kitas GD, Carruthers DM, Moots R. Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). Br J Rheumatol 1998, 37:57-63. 10.1093/rheumatology/37.1.57, 9487252.
24. Koutantji M, Harrold E, Lane SE, Pearce S, Watts RA, Scott DG. Investigation of quality of life, mood, pain, disability and disease status in primary systemic vasculitis. Arthritis Rheum 2003, 49:826-837. 10.1002/art.11471, 14673970.
25. Basu N, Jones GT, Fluck N, MacDonald AG, Pang D, Dospinescu P, Reid DM, Macfarlene GJ. Fatigue: a principle contributor to impaired quality of life in ANCA-associated vasculitis. Rheumatology (Oxford) 2010, 49:1383-1390. 10.1093/rheumatology/keq098, 3091420, 20400759.
26. Yamada H. ANCA: associated lung fibrosis. Semin Respir Crit Care Med 2011, 32:322-327. 10.1055/s-0031-1279828, 21674417.
27. Tzelepis GE, Kokosi M, Tzioufas A, Toya SP, Boki KA, Zormpala A, Moutsopoulos HM. Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur Respir J 2010, 36:116-121. 10.1183/09031936.00110109, 19926741.